ADL Amdl,

TUSTIN, Calif., Feb. 27 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that researchers from Johannes Gotenberg University, Germany, tested the diagnostic validity of the Company's DR-70(R) cancer test kit compared to CA-125, the standard test, as a tumor marker for the detection of ovarian carcinoma. The researchers simultaneously investigated the serum activities of the two tests with 61 preoperative patients with histologically confirmed ovarian carcinoma and one hundred healthy people. The specificity for DR-70(R) in the test was 100 percent (determining the presence of cancer) and sensitivity (determining the type of cancer) was 83.6 percent, 13.1 percent higher than the CA-125 test. The German researchers concluded that "DR-70(R) represents a tumor marker with which ovarian carcinoma can be diagnosed at levels of sensitivity and specificity which compare favorably to those measured with CA-125." The study is published in the German Journal of Obstetrics and Gynecology. The researchers in the paper write that the DR-70(R) immunoassay quantifies the amount of fibrin degradation products in the body, which is produced from malignant cells. DR-70(R) "has successfully been used for the detection of a number of cancers including lung, stomach, breast, rectum, liver, colon and uterus cancer," the German researchers said. Gary Dreher, AMDL CEO, said the Company is pleased with the research. He emphasized that AMDL's primary objective remains receiving U.S. Food & Drug Administration clearance to market DR-70(R), which would simultaneously increase market awareness and acceptance in the international marketplace. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements We intend that the statements in this press release that are not historical constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 of the Securities Exchange Act of 1934, as amended and are subject to numerous risks and uncertainties, including the risks (i) that the transaction described may not be completed when expected, or at all, (ii) the risk that the terms of the definitive acquisition agreements may materially differ from that disclosed herein, (iii) the risks related to the inability to obtain or meet conditions imposed for, governmental and other approvals of the transaction, including the approval by the stockholders of AMDL, (iv) risks related to the uncertainty surrounding the transaction and transactions of this type and (v) the costs related thereto. In addition, these forward-looking statements are subject to the other risks of AMDL's business, including, but not limited to, (a) AMDL's failure to complete successfully the development of new or enhanced products, (b) AMDL's future capital needs, (c) the lack of market demand for any new or enhanced products that AMDL may develop, (d) the lack of market acceptance of AMDL's products and its limited revenues to date, (e) the success of competitive products, other economic factors affecting AMDL and its markets, and (f) other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release in the event of new circumstances or unanticipated events that may occur in the future. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 First Call Analyst: FCMN Contact: DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright